1. Home
  2. ITOS vs BOC Comparison

ITOS vs BOC Comparison

Compare ITOS & BOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITOS
  • BOC
  • Stock Information
  • Founded
  • ITOS 2011
  • BOC 2009
  • Country
  • ITOS United States
  • BOC United States
  • Employees
  • ITOS N/A
  • BOC N/A
  • Industry
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • BOC
  • Sector
  • ITOS Health Care
  • BOC
  • Exchange
  • ITOS Nasdaq
  • BOC Nasdaq
  • Market Cap
  • ITOS 381.2M
  • BOC 443.8M
  • IPO Year
  • ITOS 2020
  • BOC 2017
  • Fundamental
  • Price
  • ITOS $10.17
  • BOC $13.73
  • Analyst Decision
  • ITOS Hold
  • BOC Buy
  • Analyst Count
  • ITOS 6
  • BOC 2
  • Target Price
  • ITOS $10.60
  • BOC $20.00
  • AVG Volume (30 Days)
  • ITOS 1.5M
  • BOC 170.2K
  • Earning Date
  • ITOS 08-07-2025
  • BOC 08-12-2025
  • Dividend Yield
  • ITOS N/A
  • BOC N/A
  • EPS Growth
  • ITOS N/A
  • BOC N/A
  • EPS
  • ITOS N/A
  • BOC 0.03
  • Revenue
  • ITOS $35,000,000.00
  • BOC $110,452,664.00
  • Revenue This Year
  • ITOS N/A
  • BOC $9.19
  • Revenue Next Year
  • ITOS N/A
  • BOC $6.50
  • P/E Ratio
  • ITOS N/A
  • BOC $512.85
  • Revenue Growth
  • ITOS 177.89
  • BOC 11.58
  • 52 Week Low
  • ITOS $4.80
  • BOC $13.00
  • 52 Week High
  • ITOS $18.13
  • BOC $16.20
  • Technical
  • Relative Strength Index (RSI)
  • ITOS 58.43
  • BOC 44.93
  • Support Level
  • ITOS $10.10
  • BOC $13.50
  • Resistance Level
  • ITOS $10.47
  • BOC $14.08
  • Average True Range (ATR)
  • ITOS 0.12
  • BOC 0.27
  • MACD
  • ITOS -0.06
  • BOC -0.01
  • Stochastic Oscillator
  • ITOS 23.08
  • BOC 33.78

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

About BOC Boston Omaha Corporation

Boston Omaha Corp is a us-based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. They generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.

Share on Social Networks: